ORKAOruka Therapeutics, Inc.
$82.17+428% 1Y
$82.17
$15.0552 weeks$113.05
ORKA as reported
Oruka Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q2 2024 · every figure below is as filed, with no scoring applied
- Net income
- −$133M
Net income · +6.6% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$101M
Free cash flow · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q2 2024 · 8 quarters behind |
| Net income | −$133M | +6.6% | Q2 2026 |
| EPS | −$8.64 | n/a | Q3 2024 · 7 quarters behind |
| ROE | −21% | n/a | Q2 2026 |
| ROA | −20% | n/a | Q2 2026 |
| Free cash flow | −$101M | n/a | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Oruka Therapeutics, Inc. (ORKA) · Revenue and profitRevenue and profitOruka Therapeutics, Inc. (ORKA)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Most shorted stocks